Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Raspadori

Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas Receiving Bendamustine and Rituximab

Hematological Oncology

English

Selective Influences in the B-Cell Receptor Immunoglobulin Heavy and Light Chain in Hairy Cell Leukemia

Journal of the Siena Academy of Sciences

2009

English

Related publications

Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab

British Journal of Haematology

Hematology

2018

English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma

English

Chronic Hepatitis E in Patients With Indolent Lymphoma After Treatment With Rituximab and Bendamustine

English

Pegfilgrastim in Primary Prophylaxis of Febrile Neutropenia Following Frontline Bendamustine Plus Rituximab Treatment in Patients With Indolent Non-Hodgkin Lymphoma: A Single Center, Real-Life Experience

Supportive Care in Cancer

Oncology

2016

English

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Haematologica

Hematology

2015

English

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia

English

Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis

Hematological Oncology

English

Bendamustine-Based Therapy as First-Line Treatment for Non-Hodgkin Lymphoma

English

Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Raspadori

Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas Receiving Bendamustine and Rituximab

Selective Influences in the B-Cell Receptor Immunoglobulin Heavy and Light Chain in Hairy Cell Leukemia

Related publications

Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Chronic Hepatitis E in Patients With Indolent Lymphoma After Treatment With Rituximab and Bendamustine

Pegfilgrastim in Primary Prophylaxis of Febrile Neutropenia Following Frontline Bendamustine Plus Rituximab Treatment in Patients With Indolent Non-Hodgkin Lymphoma: A Single Center, Real-Life Experience

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis

Bendamustine-Based Therapy as First-Line Treatment for Non-Hodgkin Lymphoma

Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic